Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonafexor in Impaired Renal Function and Suspected MASH
NCT06939816Phase 2Terminated
- Sponsor
- ENYO Pharma
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vonafexor in chronic kidney disease (CKD) and metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by ENYO Pharma. Primary endpoints: Change from baseline of mGFRiohexol at 16 weeks and Change from baseline of eGFRcreatinine at 16 weeks. Started Jul 2025; status: terminated.
02
Drugs
vonafexor
03
Conditions
chronic kidney disease (CKD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06939816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939816.